FDA agreed that data from the Phase 2a diSArm study support advancement of AP-SA02 to a Phase 3 study
LOS ANGELES , Nov. 18, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity,...
LOS ANGELES , Nov. 12, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity,...
LOS ANGELES , Nov. 10, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity,...
Armata Pharmaceuticals (NYSE American: ARMP) surprised Wall Street on Wednesday after its stock rocketed as much as 370% intraday on the back of groundbreaking mid-stage clinical results for its bacteriophage-based...
LOS ANGELES , Oct. 22, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity,...
LOS ANGELES , Oct. 14, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity,...
Describes the structure of phage Pa223, which is included in Armata's multi-phage anti- Pseudomonas clinical candidate, AP-PA02
LOS ANGELES , Sept. 4, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development...
Entered into secured credit agreement with Innoviva for $15 million maturing in 2029